TerrAscend Corp. (TSNDF)
OTCMKTS · Delayed Price · Currency is USD
0.7300
-0.0348 (-4.55%)
Dec 31, 2025, 9:32 AM EST
TerrAscend Revenue
TerrAscend had revenue of $65.10M in the quarter ending September 30, 2025, a decrease of -0.09%. This brings the company's revenue in the last twelve months to $299.46M, up 3.91% year-over-year. In the year 2024, TerrAscend had annual revenue of $306.68M, down -3.36%.
Revenue (ttm)
299.46M
Revenue Growth
+3.91%
P/S Ratio
0.74
Revenue / Employee
283.31K
Employees
1,163
Market Cap
220.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 306.68M | -10.65M | -3.36% |
| Dec 31, 2023 | 317.33M | 69.50M | 28.04% |
| Dec 31, 2022 | 247.83M | 53.62M | 27.61% |
| Dec 31, 2021 | 194.21M | 62.06M | 46.96% |
| Dec 31, 2020 | 132.15M | 68.34M | 107.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Northwest Biotherapeutics | 937.00K |
TerrAscend News
- 1 day ago - TerrAscend Increases Retail Footprint in New Jersey with Closing of Union Chill Dispensary Transaction - GlobeNewsWire
- 5 weeks ago - Mike Tyson and TerrAscend Team Up To Launch Tyson 2.0 In Maryland And Pennsylvania - GlobeNewsWire
- 7 weeks ago - TerrAscend outlines continued M&A expansion and targets up to 10 dispensaries in New Jersey amid strong margin gains - Seeking Alpha
- 7 weeks ago - TerrAscend Corp. (TSND:CA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - TerrAscend Corp. 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 7 weeks ago - TerrAscend Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - 3 Marijuana Stocks To Start Your Cannabis Investing Journey - MarijuanaStocks
- 2 months ago - TerrAscend Corp. (TSNDF) Is Attractively Priced Despite Fast-paced Momentum - Nasdaq